Search Result
Results for "
prostaglandin metabolite
" in MedChemExpress (MCE) Product Catalog:
7
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-109545
-
|
Unoprostone isopropyl ester; UF-021
|
Potassium Channel
|
Others
|
|
Isopropyl unoprostone (Unoprostone isopropyl ester), an analogue of a prostaglandin metabolite, is a potent large conductance Ca 2+-activated K + (BK) channels activator. Isopropyl unoprostone has antiglaucoma effects, lowering intraocular pressure (IOP) by increasing aqueous humour outflow. Isopropyl unoprostone can improve retinal sensitivity and the protection of central retinal sensitivity .
|
-
-
- HY-113366
-
|
PGJ2
|
Prostaglandin Receptor
Endogenous Metabolite
|
Neurological Disease
|
|
Prostaglandin J2 (PGJ2), an endogenous metabolite of Prostaglandin D2 (PGD2; HY-101988), is a potent PGD2 receptor (DP) agonist with Kis of 0.9 nM and 6.6 nM for hDP and hCRTH2, respectively. Prostaglandin J2 stimulates intracellular cyclic AMP production with an EC50 value of 1.2 nM. Prostaglandin J2 induces oxidative stress and neuronal apoptosis. Prostaglandin J2 induces the accumulation/aggregation of ubiquitinated (Ub) proteins. Prostaglandin J2 is highly neurotoxic and potentially contributes to many neurodegenerative conditions, including Alzheimer's (AD) and Parkinson's diseases (PD) .
|
-
-
- HY-120665
-
-
-
- HY-117659
-
|
prostaglandin D metabolite
|
Prostaglandin Receptor
|
Inflammation/Immunology
|
|
PGDM (Prostaglandin D Metabolite) is the main urinary metabolite of Prostaglandin D2 and is prone to reversible cyclization. PGDM may serve as a biomarker for the endogenous production of PGD2 or be used to evaluate the severity of acute allergic reactions .
|
-
-
- HY-137117
-
|
15-keto prostaglandin E1
|
Drug Metabolite
|
Others
|
|
15-keto-PGE1 is an inactive Prostaglandin E1 (PGE1) metabolite. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation .
|
-
-
- HY-137414
-
|
20-Hydroxy-PGE2
|
Drug Metabolite
|
Endocrinology
|
|
20-Hydroxy Prostaglandin E2 (20-Hydroxy-PGE2) is a metabolite of Prostaglandin E2 (HY-101952) that can be metabolized by cytochrome P450 .
|
-
-
- HY-113246
-
|
15-keto-PGF2α
|
Prostaglandin Receptor
Endogenous Metabolite
|
Endocrinology
|
|
15-keto-Prostaglandin F2α (15-keto-PGF2α) is a metabolite of Prostaglandin F2α. Prostaglandin F2α. Prostaglandin F2α is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist and plays a key role in the onset and progression of labour .
|
-
-
- HY-168397
-
-
-
- HY-157976
-
|
dinor-PGE1
|
Endogenous Metabolite
Prostaglandin Receptor
|
Others
|
|
Dinorprostaglandin E1 (dinor-PGE1) is the hepatocyte metabolite of prostaglandin E1 and prostaglandin E. Prostaglandin E1 and prostaglandin E inhibit glucagon, epinephrine, isoproterenol (beta-adrenergic agonist), or epinephrine-stimulated glycogenolysis when co-treated with Isoproterenol (HY-B0468) .
|
-
-
- HY-113041
-
|
PGA2; Medullin
|
Endogenous Metabolite
Apoptosis
|
Infection
Cancer
|
|
Prostaglandin A2 (PGA2), a human endogenous metabolite of PGE2, is an antitumor agent. Prostaglandin A2 induces p53-dependent apoptosis. Prostaglandin A2 also has antiviral activity .
|
-
-
- HY-168801
-
-
-
- HY-126986
-
-
-
- HY-116083
-
|
|
Endogenous Metabolite
|
Others
|
|
13,14-Dihydro-15-keto-tetranor prostaglandin D2 (Compound VI) is a prostaglandin D2 metabolite. 13,14-Dihydro-15-keto-tetranor prostaglandin D2 as a biomarker can be used to study prostaglandin D2-related diseases .
|
-
-
- HY-129953C
-
|
5-trans PGF2α tromethamine
|
Drug Derivative
|
Cardiovascular Disease
|
|
5-trans Prostaglandin F2α tromethamine is a derivative of 5-trans Prostaglandin F2α (HY-129953A). 5-trans Prostaglandin F2α is an endogenous metabolite present in blood that can be used for the research of myocardial infarction .
|
-
-
- HY-164997
-
|
15-keto PGF1α
|
Endogenous Metabolite
|
Metabolic Disease
|
|
15-keto Prostaglandin F1α (15-keto PGF1α) is a prostaglandin F1α metabolite. 15-keto Prostaglandin F1α (15-keto PGF1α) is an effective substrate for PGR-2. 15-keto Prostaglandin F1α (15-keto PGF1α) can be used to study physiological processes such as prostaglandin metabolism and lipogenesis .
|
-
-
- HY-129953B
-
|
15(R)-PGF2α
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
15(R)-Prostaglandin F2α is the isomer of 9α,11β-Prostaglandin F2α (HY-129953). 9α,11β-Prostaglandin F2α is an endogenous metabolite present in Urine that can be used for the research of Asthma .
|
-
-
- HY-129764A
-
|
17-trans-PGF3α
|
P-glycoprotein
Drug Isomer
|
Inflammation/Immunology
|
|
(17E)-Prostaglandin F3α (17-trans-PGF3α) is a double bond isomer of Prostaglandin F3α (HY-129764) and a potential metabolite of trans dietary fatty acids. (17E)-Prostaglandin F3α has anti-inflammatory activity .
|
-
-
- HY-131729
-
-
-
- HY-108568
-
|
15d-PGJ2; 15-Deoxy-Δ12,14-PGJ2
|
PPAR
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC50 of 2 µM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC50 of 7 μM .
|
-
-
- HY-170698
-
|
13,14-Dihydro-15-keto-tetranor PGE2
|
Prostaglandin Receptor
|
Endocrinology
|
|
13,14-Dihydro-15-keto-tetranor prostaglandin E2 (13,14-Dihydro-15-keto-tetranor PGE2) is a potential metabolite of Prostaglandin E2 (HY-101952) .
|
-
-
- HY-108568S
-
|
15d-PGJ2-d4; 15-Deoxy-Δ12,14-PGJ2-d4
|
PPAR
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
15-Deoxy-Δ-12,14-prostaglandin J2-d4 is the deuterium labeled 15-Deoxy-Δ-12,14-prostaglandin J2. 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC50 of 2 µM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC50 of 7 μM[1][2].
|
-
-
- HY-108568R
-
|
|
PPAR
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
15-Deoxy-Δ-12,14-prostaglandin J2 (Standard) is the analytical standard of 15-Deoxy-Δ-12,14-prostaglandin J2. This product is intended for research and analytical applications. 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC50 of 2 μM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC50 of 7 μM .
|
-
-
- HY-113205
-
|
15-keto-PGE2
|
Endogenous Metabolite
Prostaglandin Receptor
STAT
PPAR
|
Cancer
|
|
15-keto-Prostaglandin E2 is an endogenous metabolite. 15-keto-Prostaglandin E2 inhibits STAT3 activation by binding to its Cys259 residue. 15-keto-Prostaglandin E2 can bind and stabilize EP2 and EP4 receptor. 15-keto-Prostaglandin E2 inhibits breast cancer cell growth and progression. 15-keto-Prostaglandin E2 activates PPAR-γ and promotes fungal growth .
|
-
-
- HY-129953A
-
-
-
- HY-168800
-
-
-
- HY-114687
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
Others
|
|
5,7-Dihydroxy-11-ketotetranorprostanoic acid is a urinary metabolite of prostaglandin F2α and precursor to tetranor-PGF metabolites, exhibits hardly activity in blood pressure assay and smooth muscle stiumulation assay .
|
-
-
- HY-129953S
-
-
-
- HY-W408869
-
|
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
8-iso-13,14-dihydro-15-keto Prostaglandin F2α is an oxidative metabolite of 8-iso-prostaglandin F2α (HY-113209). 8-iso-13,14-dihydro-15-keto Prostaglandin F2α can be used in the study of oxidative stress-related diseases .
|
-
-
- HY-139121
-
|
15-epi Bimatoprost free acid; 15(R)-Bimatoprost free acid; 15(R)-17-phenyl trinor PGF2α
|
Prostaglandin Receptor
|
Endocrinology
|
|
15(R)-17-Phenyl trinor Prostaglandin F2α (15-epi Bimatoprost free acid) is a prostaglandin F (FP) analog that acts as an ocular hypotensive agent. The free acid 17-Phenyl trinor Prostaglandin F2α is a potent FP receptor agonist. 15(R)-17-Phenyl trinor Prostaglandin F2α is the 15-epi or "unnatural" isomer of this active free acid metabolite and has reduced FP receptor agonist activity.
|
-
-
- HY-139199
-
|
|
Drug Metabolite
|
Others
|
|
4-Hydroxyphenylbutazone is a metabolite of Phenylbutazone. Phenylbutazone, a nonsteroidal anti-inflammatory agent (NSAID), is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS) .
|
-
-
- HY-129953
-
-
-
- HY-158595
-
|
15(R),19(R)-Hydroxy PGF2α
|
Drug Derivative
|
Others
|
|
15(R),19(R)-Hydroxy prostaglandin F2α (15(R),19(R)-Hydroxy PGF2α) is an analog of 19(R)-Hydroxy-prostaglandin F2α. 19(R)-Hydroxy-prostaglandin F2α (HY-N7857) is an ω-1 hydroxylase metabolite of PGF2α found in human semen .
|
-
-
- HY-137270
-
-
-
- HY-117431
-
|
PGB3
|
PPAR
Endogenous Metabolite
|
Metabolic Disease
|
|
Prostaglandin B3 (PGB3) is a member of the class of prostaglandins B and a secondary alcohol. PGB3 exhibits a rather low affinity to human PPARγ with a Ki value greater than 1 mM compared with Ki values of 26.28 ± 8.7 μM for PGB1 and 77 ± 37.7 μM for PGB2 .
|
-
-
- HY-137504
-
-
-
- HY-118830
-
|
DK-PGD2; 15-Oxo-13,14-dihydro-PGD2; 13,14-Dihydro-15-keto-PGD2
|
Prostaglandin Receptor
|
Endocrinology
|
|
13, 14-Dihydro-15-keto prostaglandin D2 (DK-PGD2) is a PGD2 metabolite formed by the 15-hydroxyl PGDH pathway. 13, 14-Dihydro-15-keto prostaglandin D2 is a selective agonist for the DP2 receptor. 13, 14-Dihydro-15-keto prostaglandin D2 can inhibit ion flux in canine colonic mucosa preparation .
|
-
-
- HY-118548
-
|
|
Drug Metabolite
|
Endocrinology
|
|
Tetranor-PGAM is a tetranor-prostaglandin A metabolite. Tetranor-PGAM is a dehydration product of tetranor-PGEM (HY-114988). Tetranor-PGAM can be measured as a surrogate for tetranor-PGEM levels in urine .
|
-
-
- HY-113358
-
|
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
6-keto Prostaglandin F1α is an endogenous metabolite present in Cerebrospinal_Fluid, Urine and Blood that can be used for the research of Meningitis, Rheumatoid Arthritis and Cardiopulmonary Resuscitation .
|
-
-
- HY-12956B
-
|
prostaglandin F2β; PGF2β
|
Endogenous Metabolite
|
Others
|
|
(5R)-Dinoprost is a metabolite produced by cyclooxygenase metabolism of arachidonic acid. (5R)-Dinoprost (Prostaglandin F2β) induces dose-dependent release of hexose containing mucin .
|
-
-
- HY-116028
-
|
15-Deoxy-Δ12,14-PGD2
|
Endogenous Metabolite
Prostaglandin Receptor
PPAR
Src
|
Cardiovascular Disease
|
|
15-deoxy-Δ12,14-Prostaglandin D2 (15-Deoxy-Δ12,14-PGD2), a metabolite of PGD2 (HY-101988), is an agonist of prostaglandin receptor 2 (DP2). 15-deoxy-Δ12,14-Prostaglandin D2 binds to DP2 (Ki=50 nM) and induces eosinophil activation (EC50=8 nM). 15-deoxy-Δ12,14-Prostaglandin D2 also stimulates the recruitment of steroid receptor coactivator-1 (SRC-1) to peroxisome proliferator-activated receptor γ (PPARγ), inducing PPARγ-mediated transcription. 15-deoxy-Δ12,14-Prostaglandin D2 (15-Deoxy-Δ12,14-PGD2) is cytotoxic to L1210 murine leukemia cells (IC50=0.3 μg/ml) and inhibits ADP-induced platelet aggregation (IC50=320 ng/mL).
|
-
-
- HY-113113
-
|
13,14-Dihydroprostaglandin E1
|
Endogenous Metabolite
|
Metabolic Disease
|
|
13,14-Dihydro PGE1 is a metabolite of PGE1 (Prostaglandin E1) which inhibits the ADP-induced platelet aggregation (ID50 = 10.8 ng/mL platelet rich plasma) .
|
-
-
- HY-118830S1
-
|
DK-PGD2-d9; 15-Oxo-13,14-dihydro-PGD2-d9; 13,14-Dihydro-15-keto-PGD2-d9
|
Isotope-Labeled Compounds
Prostaglandin Receptor
|
Endocrinology
|
|
13,14-Dihydro-15-keto prostaglandin D2-d9 (DK-PGD2-d9) is deuterium labeled 13,14-Dihydro-15-keto prostaglandin D2. 13, 14-Dihydro-15-keto prostaglandin D2 (DK-PGD2) is a PGD2 metabolite formed by the 15-hydroxyl PGDH pathway. 13, 14-Dihydro-15-keto prostaglandin D2 is a selective agonist for the DP2 receptor. 13, 14-Dihydro-15-keto prostaglandin D2 can inhibit ion flux in canine colonic mucosa preparation .
|
-
-
- HY-118830S
-
|
DK-PGD2-d4; 15-Oxo-13,14-dihydro-PGD2-d4; 13,14-Dihydro-15-keto-PGD2-d4
|
Isotope-Labeled Compounds
|
Endocrinology
|
|
13,14-Dihydro-15-keto prostaglandin D2-d4 (DK-PGD2-d4) is deuterium labeled 13,14-Dihydro-15-keto prostaglandin D2. 13, 14-Dihydro-15-keto prostaglandin D2 (DK-PGD2) is a PGD2 metabolite formed by the 15-hydroxyl PGDH pathway. 13, 14-Dihydro-15-keto prostaglandin D2 is a selective agonist for the DP2 receptor. 13, 14-Dihydro-15-keto prostaglandin D2 can inhibit ion flux in canine colonic mucosa preparation .
|
-
-
- HY-114850A
-
|
prostaglandin F2β tromethamine; PGF2β tromethamine
|
Endogenous Metabolite
|
Others
|
|
(5R)-Dinoprost tromethamine (Prostaglandin F2β tromethamine) is a metabolite produced by the metabolism of arachidonic acid cyclooxygenase. (5R)-Dinoprost tromethamine induces dose-dependent release of hexosaccharide containing mucin .
|
-
-
- HY-113778
-
|
15-keto-17-phenyl trinor PGF2α
|
Prostaglandin Receptor
|
Endocrinology
|
|
15-keto-17-phenyl trinor Prostaglandin F2α (15-keto-17-phenyl trinor PGF2α) is an F-series prostaglandin (PG) analog. The potential metabolite of 15-keto-17-phenyl trinor Prostaglandin F2α in animals is 15-keto PG. 15-keto PG can slightly reduce the intraocular pressure (1 mm Hg) in normal cynomolgus monkeys when administered at a dose of 1 μg/eye. 15-keto-17-phenyl trinor Prostaglandin F2α is a miotic agent in cats, reducing the pupil diameter by 8 mm at a dose of 5 μg/eye.
|
-
-
- HY-W436495
-
|
6,15-Diketo-13,14-dihydro-PGF1α
|
Drug Metabolite
|
Metabolic Disease
|
|
6,15-Diketo-13,14-dihydro prostaglandin F1α (6,15-Diketo-13,14-dihydro-PGF1α) is a metabolite of prostacyclin (PGI2). 6,15-Diketo-13,14-dihydro prostaglandin F1α enhances intracellular cAMP and cholesterol metabolism in bovine arterial smooth muscle cells .
|
-
-
- HY-137024
-
|
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
15-Keto-PGA1 is a metabolite of PGA1 and has significant vasoconstrictive effects. PGA1 is also a vasoconstrictor and is more potent than equivalent doses of prostaglandin F2α (PGF2α) and angiotensin II .
|
-
-
- HY-113459S1
-
|
13,14-Dihydro-15-keto-PGF2α-d4
|
Isotope-Labeled Compounds
Prostaglandin Receptor
|
Endocrinology
|
|
13,14-Dihydro-15-keto Prostaglandin F2α-d4 (13,14-Dihydro-15-keto-PGF2α-d4) is a deuterated labeled 13,14-Dihydro-15-keto Prostaglandin F2α (HY-113208). 13,14-Dihydro-15-keto Prostaglandin F2α-d4 is an endogenous metabolite present in Blood that can be used for the research of Pregnancy .
|
-
-
- HY-114988
-
|
tetranor-PGEM
|
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
|
PGE-M is a metabolite of prostaglandin E2 (PEG2) as a biomarker of inflammation and cancer including advanced colorectal neoplasia, ovarian cancer, prostate cancer and so on. Urinary PGE-M is positively associated with obesity, smoking and lung metastases with breast cancer .
|
-
-
- HY-129397
-
|
BPG; 2,3-Dinor-11β-PGF2α; 2,3-dinor-11-epi PGF2α
|
Prostaglandin Receptor
|
Endocrinology
|
|
2,3-Dinor-11beta-prostaglandin F2alpha (2,3-Dinor-11β-PGF2α) is a metabolite of PGD2. Urinary excretion of 2,3-Dinor-11beta-prostaglandin F2alpha is increased in patients with mast cell activation disease (MCAD) and has been used as a marker of increased PGD2 levels. 2,3-Dinor-11beta-prostaglandin F2alpha levels are also increased in the urine of patients with asthma and are positively correlated with impaired lung function.
|
-
- HY-113208
-
|
13,14-Dihydro-15-keto-PGF2α
|
Endogenous Metabolite
|
Others
|
|
13,14-Dihydro-15-keto Prostaglandin F2α (13,14-Dihydro-15-keto-PGF2α) is an endogenous metabolite present in Blood that can be used for the research of Pregnancy .
|
-
- HY-139199R
-
|
|
Drug Metabolite
|
Others
|
|
4-Hydroxyphenylbutazone (Standard) is the analytical standard of 4-Hydroxyphenylbutazone. This product is intended for research and analytical applications. 4-Hydroxyphenylbutazone is a metabolite of Phenylbutazone. Phenylbutazone, a nonsteroidal anti-inflammatory agent (NSAID), is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS) .
|
-
- HY-157925
-
|
Bicyclo prostaglandin E1
|
Endogenous Metabolite
|
Others
|
|
Bicyclo-PGE1 (Bicyclo Prostaglandin E1) is a stable, base-catalyzed transformation product of the PGE1 metabolite 13,14-dihydro-15-keto PGE1. Bicyclo-PGE1 can be used to estimate the biosynthesis and metabolism of PGE1 in vivo .
|
-
- HY-116591
-
|
|
Endogenous Metabolite
|
Endocrinology
|
|
8-ISo-15-keto prostaglandin F2β is a potential metabolite of 8-Iso PGF2β via the 15-hydroxy-PG dehydrogenase pathway. 8-iso PGF2β constricts pulmonary veins in dogs and pigs .
|
-
- HY-N7857
-
|
19(R)-Hydroxy PGF2α
|
Drug Metabolite
|
Metabolic Disease
|
|
19(R)-Hydroxy-prostaglandin F2α (19(R)-hydroxy PGF2α) is an ω-1 hydroxylase metabolite of PGF2α found in human semen. The concentration of 19(R)-Hydroxy-PGFs compounds (F2α and F1α together) in fresh human semen is about 20 μg/mL. 19(R)-Hydroxy-prostaglandin F2α exhibits no activity at the FP receptor of the cat iris sphincter muscle at concentrations up to 1 μM.
|
-
- HY-113208A
-
|
11β-13,14-Dihydro-15-keto PGF2α; 11-epi-13,14-dihydro-15-keto PGF2α
|
Endogenous Metabolite
|
Others
|
|
11β-13,14-Dihydro-15-keto Prostaglandin F2α is the deviative of 13,14-Dihydro-15-keto PGF2a (HY-113208), which is an endogenous metabolite present in Blood that can be used for the research of Pregnancy .
|
-
- HY-B0641
-
|
4-Biphenylacetic acid
|
COX
|
Inflammation/Immunology
|
|
Felbinac is a metabolite of fenbufen, an orally active nonsteroidal anti-inflammatory agent and a cyclooxygenase (COX) inhibitor with an IC50 of 865.68 nM for COX1 and 976 nM for COX2. Felbinac reduces the production of prostaglandins by inhibiting COX to relieve pain, reduce inflammation and reduce fever. Felbinac can inhibit CHIKV viral activity .
|
-
- HY-118189
-
|
|
Prostaglandin Receptor
|
Inflammation/Immunology
|
|
Misoprostol acid is an active metabolite of Misoprostol. Misoprostol is a synthetic analogue of prostaglandin E1 (PGE1), extensively absorbed, and undergoes rapid de-esterification to Misoprostol acid in the gastrointestinal tract after oral administration. Misoprostol can be used for non-steroidal anti-inflammatory drug-induced (NSAID) gastric ulcers . Misoprostol is an oral agent used to induce labor .
|
-
- HY-101813
-
|
HR325
|
Dihydroorotate Dehydrogenase
DNA/RNA Synthesis
Prostaglandin Receptor
|
Inflammation/Immunology
|
|
Laflunimus (HR325) is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH). Laflunimus suppresses immunoglobulin (Ig) secretion, with IC50 values of 2.5 and 2 µM for IgM and IgG, respectively. Laflunimus also is a prostaglandin endoperoxide H synthase (PGHS) -1 and -2 inhibitor .
|
-
- HY-N4237
-
|
|
Prostaglandin Receptor
Potassium Channel
|
Inflammation/Immunology
|
|
Saikogenin D is isolated from?Bupleurum chinense, has anti-inflammatory effects. Saikogenin D activates epoxygenases that converts arachidonic acid to epoxyeicosanoids and dihydroxyeicosatrienoic acids, and the metabolites secondarily inhibit prostaglandin E2 (PGE2) production. Saikogenin D results in an elevation of [Ca 2+]i due to Ca 2+ release from intracellular stores .
|
-
- HY-118189S
-
|
|
Isotope-Labeled Compounds
Prostaglandin Receptor
|
Inflammation/Immunology
|
|
Misoprostol acid-d5 is deuterium labeled Misoprostol acid. Misoprostol acid is an active metabolite of Misoprostol. Misoprostol is a synthetic analogue of prostaglandin E1 (PGE1), extensively absorbed, and undergoes rapid de-esterification to Misoprostol acid in the gastrointestinal tract after oral administration. Misoprostol can be used for non-steroidal anti-inflammatory drug-induced (NSAID) gastric ulcers[1]. Misoprostol is an oral agent used to induce labor[2].
|
-
- HY-W740572
-
|
|
Prostaglandin Receptor
COX
|
Inflammation/Immunology
|
|
O-Desmethyl-N-deschlorobenzoyl indomethacin is a metabolite of the non-steroidal anti-inflammatory drug (NSAID) and COX inhibitor indomethacin (HY-14397). It is formed from indomethacin in isolated rabbit hepatocytes. O-Desmethyl-N-deschlorobenzoyl indomethacin (600 μM) decreases the viability of HL-60 leukemia cells when cultured with glucose oxidase. It has also been used in the synthesis of prostaglandin D2 (HY-101988) receptor antagonists.
|
-
- HY-113113S
-
|
13,14-Dihydroprostaglandin E1-d4; PGE0-d4
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Metabolic Disease
|
|
13,14-Dihydro PGE1-d4 (13,14-Dihydroprostaglandin E1-d4) is deuterium labeled 13,14-Dihydro PGE1. 13,14-Dihydro PGE1 is a metabolite of PGE1 (Prostaglandin E1) which inhibits the ADP-induced platelet aggregation (ID50 = 10.8 ng/mL platelet rich plasma) .
|
-
- HY-116889
-
|
|
Drug Metabolite
|
Others
|
|
15-keto Latanoprost is a potential metabolite of latanoprost (HY-B0577) when administered to animals. 15-keto Latanoprost is also one of the common minor impurities found in commercial preparations of the bulk drug compound. Although much less potent that the parent compound latanoprost, 15-keto latanoprost still retains the ability to produce a small but measurable decrease (1 mm Hg) in the intraocular pressure of normal cynomolgus monkeys when administered at a dose of 1 μg/eye.1 15-keto Latanoprost is also a miotic in the normal cat eye, causing an 8 mm Hg reduction in pupillary diameter at 5 μg/eye. Again, this is not as potent as many other F-type prostaglandins; for example, prostaglandin F2α will produce this degree of miosis at a dose of less than 1 μg/eye.
|
-
- HY-168382A
-
|
|
Prostaglandin Receptor
Endogenous Metabolite
|
Others
|
|
5S(6R)-EET is the metabolite of Arachidonic acid (HY-109590). 5S(6R)-EET activates the synthesis of endogenous prostaglandin (PGE2), which inhibits the Na + absorption, increases the intracellular Ca 2+, and promotes the depolarization of transmembrane voltage. 5S(6R)-EET is more active than 5R(6S)-EET (HY-168382) .
|
-
- HY-168382
-
|
|
Prostaglandin Receptor
Endogenous Metabolite
|
Others
|
|
5R(6S)-EET is the metabolite of Arachidonic acid (HY-109590). 5R(6S)-EET activates the synthesis of endogenous prostaglandin (PGE2), which inhibits the Na + absorption, increases the intracellular Ca 2+, and promotes the depolarization of transmembrane voltage. 5R(6S)-EET exhibits stereoselectivity with less effectness than 5S(6R)-EET (HY-168382A) .
|
-
- HY-137547
-
|
|
Prostaglandin Receptor
|
Metabolic Disease
|
|
20-hydroxy Prostaglandin F2α (20-hydroxy PGF2α) is the ω-oxidation product of PGF2α. Cultured type II alveolar cells from pregnant rabbits metabolize exogenous PGF2α via microsomal cytochrome P450 ω-oxidation, producing 20-hydroxy PGF2α and its 15-hydroxy PGDH metabolites. Cells from male rabbits exhibit only the 15-hydroxy PGDH pathway.
|
-
- HY-118816
-
|
11-epi PGF2α-EA; 11β-PGF2α-EA; 11β-Prostamide F2α
|
Drug Metabolite
|
Metabolic Disease
|
|
11β-Prostaglandin F2α ethanolamide (11β-PGF2α-EA) is the theoretical hepatic metabolite of PGD2-EA, produced during COX-2 metabolism of the endogenous cannabinoid AEA which is found in brain, liver, and other mammalian tissues.1 AEA can be used directly by COX-2 and specific PG synthase to produce ethanolamide congeners of the classical PGs. PGD2-EA is formed in activated RAW 264.7 cells treated with AEA.
|
-
- HY-W587743
-
|
AMK hydrochloride
|
Prostaglandin Receptor
PGE synthase
COX
Reactive Oxygen Species
|
Neurological Disease
Metabolic Disease
|
|
N1-Acetyl-5-methoxykynuramine (AMK) hydrochloride is an active metabolite of the neurohormone melatonin (HY-B0075). N1-Acetyl-5-methoxykynuramine hydrochloride (200 µM) effectively scavenges singlet oxygen (ROS).1 It also inhibits the production of prostaglandin E2 (PGE2) and prostaglandin D2 (PGD2) induced by epinephrine and arachidonic acid in a concentration- and time-dependent manner, and suppresses the increase in COX-2 levels induced by LPS (HY-D1056) in RAW 264.7 macrophages at a concentration of 500 µM. In a mouse model of Parkinson's disease induced by MPTP (HY-15608), N1-Acetyl-5-methoxykynuramine hydrochloride (20 mg/kg) reduces the increase in lipid peroxidation in the cytosol and mitochondria of the substantia nigra and striatum. N1-Acetyl-5-methoxykynuramine hydrochloride can be used in research on metabolic and neurological diseases
|
-
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-108568S
-
|
|
|
15-Deoxy-Δ-12,14-prostaglandin J2-d4 is the deuterium labeled 15-Deoxy-Δ-12,14-prostaglandin J2. 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC50 of 2 µM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC50 of 7 μM[1][2].
|
-
-
- HY-129953S
-
|
|
|
9α,11β-Prostaglandin F2α-d4 is a deuterated labeled 9α,11β-Prostaglandin F2α . 9α,11β-Prostaglandin F2α is an endogenous metabolite present in Urine that can be used for the research of Asthma .
|
-
-
- HY-118830S1
-
|
|
|
13,14-Dihydro-15-keto prostaglandin D2-d9 (DK-PGD2-d9) is deuterium labeled 13,14-Dihydro-15-keto prostaglandin D2. 13, 14-Dihydro-15-keto prostaglandin D2 (DK-PGD2) is a PGD2 metabolite formed by the 15-hydroxyl PGDH pathway. 13, 14-Dihydro-15-keto prostaglandin D2 is a selective agonist for the DP2 receptor. 13, 14-Dihydro-15-keto prostaglandin D2 can inhibit ion flux in canine colonic mucosa preparation .
|
-
-
- HY-118830S
-
|
|
|
13,14-Dihydro-15-keto prostaglandin D2-d4 (DK-PGD2-d4) is deuterium labeled 13,14-Dihydro-15-keto prostaglandin D2. 13, 14-Dihydro-15-keto prostaglandin D2 (DK-PGD2) is a PGD2 metabolite formed by the 15-hydroxyl PGDH pathway. 13, 14-Dihydro-15-keto prostaglandin D2 is a selective agonist for the DP2 receptor. 13, 14-Dihydro-15-keto prostaglandin D2 can inhibit ion flux in canine colonic mucosa preparation .
|
-
-
- HY-113459S1
-
|
|
|
13,14-Dihydro-15-keto Prostaglandin F2α-d4 (13,14-Dihydro-15-keto-PGF2α-d4) is a deuterated labeled 13,14-Dihydro-15-keto Prostaglandin F2α (HY-113208). 13,14-Dihydro-15-keto Prostaglandin F2α-d4 is an endogenous metabolite present in Blood that can be used for the research of Pregnancy .
|
-
-
- HY-118189S
-
|
|
|
Misoprostol acid-d5 is deuterium labeled Misoprostol acid. Misoprostol acid is an active metabolite of Misoprostol. Misoprostol is a synthetic analogue of prostaglandin E1 (PGE1), extensively absorbed, and undergoes rapid de-esterification to Misoprostol acid in the gastrointestinal tract after oral administration. Misoprostol can be used for non-steroidal anti-inflammatory drug-induced (NSAID) gastric ulcers[1]. Misoprostol is an oral agent used to induce labor[2].
|
-
-
- HY-113113S
-
|
|
|
13,14-Dihydro PGE1-d4 (13,14-Dihydroprostaglandin E1-d4) is deuterium labeled 13,14-Dihydro PGE1. 13,14-Dihydro PGE1 is a metabolite of PGE1 (Prostaglandin E1) which inhibits the ADP-induced platelet aggregation (ID50 = 10.8 ng/mL platelet rich plasma) .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
